In recent years, speed and accuracy in viral diagnostics have become global priorities. In this scenario, electronic nose (e-nose) technology has demonstrated revolutionary potential. PCA Technologies, through the applications of the PEN3 (Portable Electronic Nose), enables the immediate and non-invasive detection of SARS-CoV-2.
The principle behind using the PEN3 for COVID-19 lies in the analysis of VOCs (Volatile Organic Compounds), the volatile organic compounds emitted by human metabolism. A viral infection alters cellular biochemical processes, producing a specific “olfactory fingerprint” (biomarker) detectable in exhaled breath. The PEN3, thanks to its sensor chamber equipped with Metal Oxide Sensors (MOS), is capable of capturing these infinitesimal variations in real time.
The integration of the PEN3 electronic nose into screening protocols offers competitive advantages over traditional methods:
- Real-time results: Unlike PCR tests that require hours or days, the PEN3 provides a response in minutes.
- Non-invasiveness: Sampling occurs via exhaled air, eliminating the discomfort of the nasopharyngeal swab and increasing patient compliance.
- Extreme portability: Thanks to its small size, the PEN3 can be used in airports, schools, hospitals, and at large events.
- Reduced test cost: Once the instrument is acquired, the operating cost per individual screening is extremely low.
The PEN3 represents the meeting point between advanced sensor technology and urgent diagnostic needs, offering a ready-to-use solution for both environmental and clinical monitoring.
